• A recent study demonstrates that the TLR3/4-TBK1-IRF3 pathway connects environmental insults to IL-33 induction in skin and pancreatic inflammation.

• Scientists screened an FDA-approved drug library and found pitavastatin effectively suppresses IL-33 by blocking TBK1 membrane recruitment via the mevalonate pathway.

• Pitavastatin was shown to prevent chronic pancreatitis and its cancerous outcomes in an IL-33-dependent manner.

• This pathway is highly active in human chronic pancreatitis and pancreatic cancer.

• Pitavastatin use correlates with a reduced risk of these conditions, highlighting statins as a potential preventative strategy against inflammation-induced cancer.

• Future research will focus on exploring the impact of statins on preventing cancer development linked to chronic inflammation in the liver and gastrointestinal tract. 

• Additionally, efforts will be made to identify other novel therapeutic approaches to suppress cancer-prone chronic inflammation.

Click here to read more.